Scolr to co-develop flu application

By Elaine Rigoli

Tampa, Fla., Sept. 22 - Scolr Pharma, Inc. said it entered into a research collaboration with a U.S.-based biopharmaceutical company to develop an oral formulation of an antiviral compound using Scolr's proprietary CDT drug-delivery platform.

The Bellevue, Wash.-based pharmaceutical company said the compound under development has the potential to be used as a treatment against influenza.

"We believe this collaborative agreement is another important affirmation of the breadth of our proprietary CDT drug-delivery technology," senior vice president Alan M. Mitchel said in a news release.

"We look forward to working closely with our partner on this potentially important new pharmaceutical application. This is our fourth partnering relationship announced over the last several quarters."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.